StreetAlpha.app
Home › Stocks › AGEN

Agenus Inc (AGEN)

Healthcare
$5.97
▼ −2.77%
LAST CLOSE · NOV 20

Agenus is a Lexington, Massachusetts biotechnology company developing immunotherapies for cancer and autoimmune diseases. It last closed at $5.97 on Nov 20, down 2.77% on the day. The next earnings report for AGEN is expected around Mon, Mar 15, 2027. For the quarter ended Sep 2026, AGEN reported EPS of $0.02 on revenue of $31.5M, with revenue up 4.1% from a year ago. Over its last 8 reports the stock moved an average of 9.2% the session after earnings.

AI Auto Pilots
Is AGEN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AGEN.

Key Stats

Last 12 months
Results
Revenue
$133.9M
+25.4% vs a year ago
Net income
$30.8M
23.0% margin
EPS (diluted)
$0.23
Free cash flow
−$103.9M
−77.5% margin
Valuation
Market cap
$270.1M
45.2M shares
P/E
26.0
Price over 12 month EPS
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$66.9M
At Sep 30
Debt
$29.8M
At Sep 30
Shareholder equity
−$105.4M
Shares outstanding
45.2M
At Nov 3
CEOGaro H. Armen
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $295.7M$295.7MFY2021FY2022: $98.0M$98.0MFY2022FY2023: $156.3M$156.3MFY2023FY2024: $103.5M$103.5MFY2024FY2025: $114.2M$114.2MFY2025

From AGEN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · Time not announced
Reported EPS
$0.02
Quarter ended Sep 2026
Year ago EPS
$1.94
−99.0% on a GAAP basis
Revenue
$31.5M
+4.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.94Dec '24Mar 2025: -$1.03Mar '25Jun 2025: -$1.00Jun '25Sep 2025: $1.94Sep '25Dec 2025: -$0.37Dec '25Mar 2026: $1.02Mar '26Jun 2026: -$0.01Jun '26Sep 2026: $0.02Sep '26Latest $0.02
Revenue by quarter
Dec 2024: $26.8MDec '24Mar 2025: $24.1MMar '25Jun 2025: $25.7MJun '25Sep 2025: $30.2MSep '25Dec 2025: $34.2MDec '25Mar 2026: $33.7MMar '26Jun 2026: $34.5MJun '26Sep 2026: $31.5MSep '26Latest $31.5M
How AGEN moved after its last 8 reports
Average move the session after a report ±9.2%
Nov 5, 2026Time not announced−7.6%
Aug 6, 2026Time not announced−3.7%
May 11, 2026Time not announced−14.7%
Mar 16, 2026Time not announced+6.1%
Nov 10, 2025Time not announced+5.8%
Aug 11, 2025Time not announced−11.0%
May 12, 2025Time not announced+20.3%
Mar 11, 2025Time not announced−4.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AGENStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AGEN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AGEN

Technical Analysis

AGEN · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 12% below its 20 day and 22% below its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 39). The nearest support is the Pivot S1 at $5.83, and the nearest resistance the Pivot at $6.04.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 8.5%/day
Key levels
$10.3152 week high+72.7%
$7.30Swing high (Oct 29)+22.3%
$7.2650 day average+21.6%
$6.92100 day average+15.9%
$6.6820 day average+11.9%
$6.19Pivot R1+3.7%
$6.04Pivot+1.2%
$5.97Last close
$5.83Pivot S1−2.3%
$5.19200 day average−13.1%
$3.10Swing low (Jul 10)−48.1%
$2.7152 week low−54.6%
Indicators
RSI (14)38.76Weak, oversold below 30Neutral
MACD-0.24Below its signal lineBearish
Stochastic19.5Near the bottom of its rangeOversold
ADX (14)20.1Weak trend
Williams %R-88.2Oversold below −80, overbought above −20Oversold
CCI (20)-133.1Oversold below −100, overbought above 100Oversold
Rate of change−16.5%Change over 10 sessionsBearish
ATR (14)$0.51Typical daily range, 8.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for AGEN

What happened before

See how AGEN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AGEN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AGEN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AGENHow many large options trades hit AGEN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AGEN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲77 buying vs 44 selling
  • ▲Held by funds +26.6 pts
  • ▲Funds holding +22
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding127105+21.0%
In funds' top 1000–
Held by funds58.1%31.6%+26.6 pts
New / increased41 / 3633 / 31+20.3%
Reduced / sold out24 / 2019 / 15+29.4%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AGEN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AGEN is in one of them and how their past AGEN trades turned out.

AGEN in the AI portfolios
Loading…

AGEN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AGEN in an article yet. Here's the latest on the wider market.

AGEN in the news

About Agenus

Agenus is a biotechnology company based in Lexington, Massachusetts. It is developing immunotherapy product candidates aimed at cancer and autoimmune diseases. Its target customers are physicians and patients, and sales depend heavily on coverage and reimbursement from insurers and government healthcare programs. Its product candidates have not yet received marketing approval, and it competes with established treatments such as chemotherapy and radiation therapy.

Headquarters
Lexington, MA
Founded
1994